IgGA: A "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions

Chemistry and Biology

Volumn 21, Issue 12, 2014, Pages 1603-1609

  Kelton, William ^a   Mehta, Nishant ^a   Charab, Wissam ^a   Lee, Jiwon ^a   Lee, Chang Han ^a   Kojima, Takaaki ^c   Kang, Tae Hyun ^a   Georgiou, George ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; TRASTUZUMAB; COMPLEMENT; FC RECEPTOR; FC RECEPTOR IIA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BETA SHEET; BINDING SITE; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION CONSTANT; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROGEN BOND; MACROPHAGE; NEUTROPHIL; PHAGOCYTOSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ENGINEERING; SURFACE PLASMON RESONANCE; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; CROSS REACTION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTROPHILS; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, FC; RECEPTORS, IGG;

EID: 84919949974     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.10.017     Document Type: Article

References (34)

1. J.D. Atkin, R.J. Pleass, R.J. Owens, and J.M. Woof Mutagenesis of the human IgA1 heavy chain tailpiece that prevents dimer assembly J. Immunol. 157 1996 156 159
2. J.E. Bakema, S.H. Ganzevles, D.M. Fluitsma, M.W. Schilham, R.H.J. Beelen, T. Valerius, S. Lohse, M.J. Glennie, J.P. Medema, and M. van Egmond Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy J. Immunol. 187 2011 726 732
3. A. Beck, and J.M. Reichert Marketing approval of mogamulizumab: a triumph for glyco-engineering MAbs 4 2012 419 425
4. P. Boross, S. Lohse, M. Nederend, J.H.M. Jansen, G. van Tetering, M. Dechant, M. Peipp, L. Royle, L.P. Liew, and L. Boon IgA EGFR antibodies mediate tumour killing in vivo EMBO Mol. Med. 5 2013 1213 1226
5. P. Bruhns, B. Lannascoli, P. England, D.A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses Blood 113 2009 3716 3725
6. L. Carayannopoulos, J.M. Hexham, and J.D. Capra Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1 J. Exp. Med. 183 1996 1579 1586
7. K.R. Chintalacharuvu, L.U. Vuong, L.A. Loi, J.W. Larrick, and S.L. Morrison Hybrid IgA2/IgG1 antibodies with tailor-made effector functions Clin. Immunol. 101 2001 21 31
8. S.Y. Chu, I. Vostiar, S. Karki, G.L. Moore, G.A. Lazar, E. Pong, P.F. Joyce, D.E. Szymkowski, and J.R. Desjarlais Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies Mol. Immunol. 45 2008 3926 3933
9. M. Dechant, and T. Valerius IgA antibodies for cancer therapy Crit. Rev. Oncol. Hematol. 39 2001 69 77
10. M. Dechant, T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J.G.J. van de Winkel, and T. Valerius Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor J. Immunol. 179 2007 2936 2943
11. J.R. Desjarlais, and G.A. Lazar Modulation of antibody effector function Exp. Cell Res. 317 2011 1278 1285
12. C. Ferrara, S. Grau, C. Jäger, P. Sondermann, P. Brünker, I. Waldhauer, M. Hennig, A. Ruf, A.C. Rufer, and M. Stihle Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose Proc. Natl. Acad. Sci. USA 108 2011 12669 12674
13. A.D. Gregory, and A.M. Houghton Tumor-associated neutrophils: new targets for cancer therapy Cancer Res. 71 2011 2411 2416
14. A.B. Herr, E.R. Ballister, and P.J. Bjorkman Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc Nature 423 2003 614 620
15. A.B. Herr, C.L. White, C. Milburn, C. Wu, and P.J. Bjorkman Bivalent binding of IgA1 to FcalphaRI suggests a mechanism for cytokine activation of IgA phagocytosis J. Mol. Biol. 327 2003 645 657
16. P.M. Hogarth, and G.A. Pietersz Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond Nat. Rev. Drug Discov. 11 2012 311 331
17. S.T. Jung, W. Kelton, T.H. Kang, D.T.W. Ng, J.T. Andersen, I. Sandlie, C.A. Sarkar, and G. Georgiou Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity ACS Chem. Biol. 8 2013 368 375
18. T. Keler, P.K. Wallace, L.A. Vitale, C. Russoniello, K. Sundarapandiyan, R.F. Graziano, and Y.M. Deo Differential effect of cytokine treatment on Fc α receptor I- and Fc γ receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages J. Immunol. 164 2000 5746 5752
19. S. Lohse, C. Brunke, S. Derer, M. Peipp, P. Boross, C. Kellner, T. Beyer, M. Dechant, J.G. van der Winkel, J.H. Leusen, and T. Valerius Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages J. Biol. Chem. 287 2012 25139 25150
20. A. Mantovani, M.A. Cassatella, C. Costantini, and S. Jaillon Neutrophils in the activation and regulation of innate and adaptive immunity Nat. Rev. Immunol. 11 2011 519 531
21. T.S. Mattu, R.J. Pleass, A.C. Willis, M. Kilian, M.R. Wormald, A.C. Lellouch, P.M. Rudd, J.M. Woof, and R.A. Dwek The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions J. Biol. Chem. 273 1998 2260 2272
22. M. Narayan, J.A. Wilken, L.N. Harris, A.T. Baron, K.D. Kimbler, and N.J. Maihle Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells Cancer Res. 69 2009 2191 2194
23. F. Nimmerjahn, and J.V. Ravetch Translating basic mechanisms of IgG effector activity into next generation cancer therapies Cancer Immun. 12 2012 13
24. M.A. Otten, E. Rudolph, M. Dechant, C.W. Tuk, R.M. Reijmers, R.H. Beelen, J.G. van de Winkel, and M. van Egmond Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors J. Immunol. 174 2005 5472 5480
25. V. Pascal, B. Laffleur, A. Debin, A. Cuvillier, M. van Egmond, D. Drocourt, L. Imbertie, C. Pangault, K. Tarte, G. Tiraby, and M. Cogné Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells Haematologica 97 2012 1686 1694
26. A. Rhodes, B. Jasani, E. Anderson, A.R. Dodson, and A.J. Balaton Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries Am. J. Clin. Pathol. 118 2002 408 417
27. A. Roos, L.H. Bouwman, D.J. van Gijlswijk-Janssen, M.C. Faber-Krol, G.L. Stahl, and M.R. Daha Human IgA activates the complement system via the mannan-binding lectin pathway J. Immunol. 167 2001 2861 2868
28. T.R. Simpson, F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J.Y. Henry, H. Yagita, and J.D. Wolchok Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J. Exp. Med. 210 2013 1695 1710
29. J.C. Souto, L. Vila, and A. Brú Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors Med. Res. Rev. 31 2011 311 363
30. M. van Egmond, and J.E. Bakema Neutrophils as effector cells for antibody-based immunotherapy of cancer Semin. Cancer Biol. 23 2013 190 199
31. M. van Egmond, A.J. Hanneke van Vuuren, and J.G.J. van de Winkel The human Fc receptor for IgA (Fc α RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis Immunol. Lett. 68 1999 83 87
32. M. van Egmond, C.A. Damen, A.B. van Spriel, G. Vidarsson, E. van Garderen, and J.G.J. van de Winkel IgA and the IgA Fc receptor Trends Immunol. 22 2001 205 211
33. J.M. Woof, and M.A. Kerr The function of immunoglobulin A in immunity J. Pathol. 208 2006 270 282
34. X. Zhou, W. Hu, and X. Qin The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy Oncologist 13 2008 954 966